Abstract：
Seven of the 11 newer medications recently or soon to be approved to treat rheumatologic diseases discussed in this article are biologic agents and reflect the current ability of science to target specific components of the immune system. The other agents are molecules that are directed against specific immune pathway targets as well. All have shown superiority to placebo and in some cases have been compared to currently accepted therapies. Safety issues are generally centered around infections due to the immune-interrupting nature of these therapies.
摘要：
本文讨论的最近或即将批准用于治疗风湿病的11种新型药物中，有7种是生物制剂，反映了当前科学针对免疫系统特定成分的能力。其他试剂也是针对特定免疫途径靶标的分子。所有这些都显示出优于安慰剂，并且在某些情况下已与目前接受的疗法进行了比较。由于这些疗法的免疫中断性质,安全问题通常集中在感染周围。
